egnite to focus on improving the quality of care for all cardiovascular patients in the U.S.
“This is the first prevalence study out of one of the largest echo databases in the world, underscoring the potential for groundbreaking research from this tremendous resource. Our work expands by an order of magnitude the sample size and generalizability of previous work in a large contemporary cohort.” J. Matthew
BACKGROUND Valvular heart disease (VHD) is progressive and deadly, requiring timely diagnosis for optimal outcomes1 Prior landmark analyses of VHD prevalence in the United States (US), including the Framingham Heart Study2 and Nkomo et al.3 , have reported notable prevalence of disease However, these analyses were limited in scope (e.g.,
Data To Be Presented at 2022 ACC Annual Meeting Demonstrate Valve Disease is More Common in Women in the U.S…
The CardioCare platform has partnered with healthcare systems extensively to help elevate the standard of structural heart patient care. Data uncovered from
this experience have helped us understand what best-in-class patient care looks like nationwide.